Probiotics prevent dysbiosis and the raise in blood pressure in genetic hypertension.
Probiotics Prevent Dysbiosis and the Raise in Blood Pressure in Genetic Hypertension: Role of Short-chain Fatty Acids.
AI Summary
Key Findings
Abstract
SCOPE: The objective of this study was to determine the cardiovascular effects of the probiotics Bifidobacterium breve CECT7263 (BFM) and Lactobacillus fermentum CECT5716 (LC40), and the short chain fatty acids butyrate and acetate in spontaneously hypertensive rats (SHR). METHODS AND RESULTS: Ten five-weeks old Wistar Kyoto rats (WKY) and fifty aged-matched SHR were randomly distributed into six groups: control WKY, control SHR, treated SHR-LC40, treated SHR-BMF, treated SHR-butyrate, and treated SHR-acetate. Chronic treatments with LC40 or BFM increased butyrate-producing bacteria and prevented the blood pressure increase in SHR. Oral treatment with butyrate or acetate also prevented the increase in both blood pressure and Firmicutes/Bacteroidetes ratio. All treatments restored the Th17/Treg balance in mesenteric lymph nodes, normalized endotoxemia, and prevented the impairment of endothelium-dependent relaxation to acetylcholine, as a result of reduced NADPH oxidase-driven reactive oxygen species production. These protective effects might be mediated by both the reduction in vascular lipopolysaccharide/toll-like receptor 4 pathway and the increase in Treg infiltration in the vasculature. CONCLUSION: The probiotics LC40 and BFM prevent dysbiosis and the development of endothelial dysfunction and high blood pressure in genetic hypertension. These effects seems to be related to endotoxemia reduction and to increase Treg accumulation in the vasculature. This article is protected by copyright. All rights reserved.
Affiliation
Iñaki Robles-Vera
External References
- PubMed ID:
- 31953983
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.